Influenza Therapeutics in Clinical Practice—Challenges and Recent Advances
Authors:
Open Access
- 10 February 2020
- journal article
- research article
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Medicine
- Vol. 11 (4) , a038463
Abstract
In the last few years, several new direct-acting influenza antivirals have been licensed, and others have advanced in clinical development. The increasing diversity of antiviral classes should allow an adequate public health response should a resistant virus to one agent or class widely circulate. One new antiviral, baloxavir marboxil, has been approved in the United States for treatment of influenza in those at high risk of developing influenza-related complications. Except for intravenous zanamivir in European Union countries, no antivirals have been licensed specifically for the indication of severe influenza or hospitalized influenza. This review addresses recent clinical developments involving selected polymerase inhibitors, neuraminidase inhibitors, antibody-based therapeutics, and host-directed therapies. There are many knowledge gaps for most of these agents because some data are not published and multiple pivotal studies are in progress at present. This review also considers important clinical research issues, including regulatory pathways, study designs, endpoints, and target populations encountered during the clinical development of novel therapeutics.Keywords
This publication has 122 references indexed in Scilit:
- T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 VirusesIn VitroJournal of Virology, 2013
- Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trialJournal of Infection and Chemotherapy, 2013
- A Highly Conserved Neutralizing Epitope on Group 2 Influenza A VirusesScience, 2011
- Duration of viral shedding in hospitalized patients infected with pandemic H1N1BMC Infectious Diseases, 2011
- Systematic review of influenza resistance to the neuraminidase inhibitorsBMC Infectious Diseases, 2011
- Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate (CS-8958) versus Oseltamivir as Treatment for Children with Influenza Virus InfectionAntimicrobial Agents and Chemotherapy, 2010
- Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post-translational LevelJournal of Biological Chemistry, 2009
- Animal models for the study of influenza pathogenesis and therapyAntiviral Research, 2009
- Antibody Recognition of a Highly Conserved Influenza Virus EpitopeScience, 2009
- Current and future antiviral therapy of severe seasonal and avian influenzaAntiviral Research, 2008